Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
Hampp
Christian
C
Kauf
Teresa L
TL
Winterstein
Almut G
AG
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002017:Budgets; D003362:Cost-Benefit Analysis; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D000069455:Palivizumab; D015995:Prevalence; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D040242:Risk Reduction Behavior; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab